Published in Br J Cancer on August 01, 2000
The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol (2001) 3.54
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol (2008) 3.03
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.99
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax (2002) 1.16
Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev (2013) 1.03
Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer (2002) 1.00
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC Cancer (2009) 1.00
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer (2005) 0.97
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2010) 0.95
Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. Respir Res (2013) 0.91
Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett (2013) 0.88
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer (2004) 0.87
Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ (2007) 0.84
Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.83
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer (2002) 0.82
Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother (2012) 0.82
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer (2004) 0.82
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Invest New Drugs (2007) 0.81
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer (2003) 0.77
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol (2010) 0.77
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. BMC Med Res Methodol (2011) 0.77
Not all depression is created equal: sex interacts with disease to precipitate depression. Biol Sex Differ (2013) 0.77
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines. J Exp Clin Cancer Res (2009) 0.76
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC. Br J Cancer (2005) 0.75
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther (2009) 0.75
Lung cancer. BMJ Clin Evid (2009) 0.75
Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax (2003) 0.75
Chemotherapy and quality of life in advanced NSCLC. Br J Cancer (2001) 0.75
Specific anticancer treatments in the last 3 months of life: a French experience. Support Care Cancer (2012) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer (1994) 3.45
Gemcitabine--a safety review. Anticancer Drugs (1998) 1.74
Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol (1989) 1.68
Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer (1995) 1.52
Quality of life in cancer trials. Br Med J (Clin Res Ed) (1985) 1.44
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs (1997) 1.36
Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res (1997) 1.33
Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. Qual Life Res (1994) 1.26
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer (1989) 1.20
Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer (1999) 1.18
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur J Cancer (1997) 1.11
Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur J Cancer (1997) 1.00
Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. Eur J Cancer (1998) 0.97
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs (1995) 0.90
Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer (1996) 0.89
Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol (1996) 0.85
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (2008) 6.50
Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut (2008) 5.86
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke (1991) 4.21
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 4.03
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol (1996) 3.68
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
District cancer physicians. Report of a Working Group of the Association of Cancer Physicians. J R Coll Physicians Lond (1987) 3.39
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol (2008) 3.31
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (2010) 3.21
Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol (1999) 3.20
Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke (1992) 3.09
Transformation of alveolar type 2 cells to type 1 cells following exposure to NO2. Exp Mol Pathol (1975) 3.07
Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg (2010) 3.03
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Renewal of alveolar epithelium in the rat following exposure to NO2. Am J Pathol (1973) 2.80
The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer (2002) 2.80
Rapid diagnosis of tuberculous meningitis by latex particle agglutination. Lancet (1984) 2.78
Optimizing nebulization practice within a large teaching hospital: easier said than done. Respir Med (1995) 2.74
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax (1996) 2.58
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Diurnal rhythms in airway obstruction. Br J Dis Chest (1979) 2.48
Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol (2000) 2.46
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Adverse reaction to ipratropium bromide. Br Med J (Clin Res Ed) (1982) 2.35
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
The deterioration of hearing with age: frequency selectivity, the critical ratio, the audiogram, and speech threshold. J Acoust Soc Am (1982) 2.29
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet (1990) 2.25
Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax (2001) 2.24
Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J (2002) 2.24
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax (2004) 2.22
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst (1993) 2.22
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol (2002) 2.14
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg (2004) 2.14
Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet (1974) 2.12
Lung cancer: the importance of seeing a respiratory physician. Eur Respir J (2003) 2.08
Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol (2005) 2.04
Measuring the quality of life following cancer treatment. Hosp Med (1998) 2.03
Comparison of the effect of alprenolol and propranolol on specific airway conductance in asthmatic subjects. Br Med J (1970) 2.02
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med (1996) 1.99
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer (2001) 1.97
Pressure waves in so-called low-pressure hydrocephalus. Lancet (1972) 1.94
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1996) 1.93
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A (2000) 1.88
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer (1998) 1.88
Renewal of the terminal bronchiolar epithelium in the rat following exposure to NO2 or O3. Lab Invest (1976) 1.85
A prospective, randomised study of endoscopy and radiology in acute upper-gastrointestinal-tract bleeding. Lancet (1977) 1.81
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum Mol Genet (2001) 1.81
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Evidence of a locus for orofacial clefting on human chromosome 6p24 and STS content map of the region. Hum Mol Genet (1995) 1.75
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) (1981) 1.75
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
Method of using pressurized aerosols. Br Med J (1975) 1.69
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
The contribution of childhood obesity to adult carotid intima-media thickness: the Bogalusa Heart Study. Int J Obes (Lond) (2008) 1.66
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
A comprehensive service for patients with cancer in a district general hospital. Br Med J (Clin Res Ed) (1986) 1.63
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer (2002) 1.62
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems? Med Care (2001) 1.61
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer (1996) 1.57
A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. Br J Cancer (2001) 1.56
Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer (2001) 1.56
Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest (1982) 1.55
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer (1995) 1.52
Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun (1994) 1.51
The significant unmet needs of cancer patients: probing psychosocial concerns. Support Care Cancer (2001) 1.51
Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest (1984) 1.50
Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst (1993) 1.49
A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol (1978) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer (2009) 1.44